Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Nitroimidazole antimycobacterial (MDR-TB)

Delamanid

Brand names: Deltyba

Delamanid is an antimycobacterial agent used as part of an appropriate combination regimen for multidrug-resistant pulmonary tuberculosis.

Dosing — no UK product information found

We found no UK product information (SmPC) for this medicine or presentation on the eMC or MHRA Products (checked October 2026). It may be unlicensed in the UK, imported, a medical device, or no longer marketed. ClinCalc Pro shows only doses it can trace to official product information, so none is shown — follow your specialist service or local guideline.

Clinical monograph

How it works

It inhibits the synthesis of mycolic acids, key components of the mycobacterial cell wall, thereby impairing the integrity of Mycobacterium tuberculosis.

Prescribing in practice

  • Delamanid prolongs the QT interval, so obtain a baseline electrocardiogram and correct electrolyte abnormalities, with caution when combined with other QT-prolonging drugs.
  • It must only be used within a combination regimen designed by a specialist to prevent emergence of further resistance.
  • Hypoalbuminaemia increases the risk of QT prolongation and warrants particular caution.

Monitoring

Monitor the electrocardiogram and serum electrolytes, including potassium, periodically throughout treatment.

Counselling the patient

  • Take every dose as prescribed and with food, and do not stop the regimen early as this risks treatment failure and resistance.
  • Report palpitations, fainting, or dizziness, which may indicate a heart-rhythm effect.

Evidence & guidelines

Use in multidrug-resistant tuberculosis is supported by WHO recommendations and the controlled trials that informed its regulatory approval.

Reference: WHO MDR-TB; BTS/SIGN; UKHSA; SmPC; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways